A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

MLA

Sattva S. Neelapu, et al. “A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).” Blood, vol. 134, Nov. 2019, p. 1546. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........3af209108dd0bd2f17aba784f6402bfd&authtype=sso&custid=ns315887.

APA

Sattva S. Neelapu, Roberto N. Miranda, Nathan Fowler, Auris Huen, Swami P. Iyer, Loretta J. Nastoupil, Sairah Ahmed, Hun Ju Lee, Felipe Samaniego, Ethan Burns, Ranjit Nair, Feng Lei, Simrit Parmar, Madeleine Duvic, Chitra Hosing, Jason R. Westin, & Yago Nieto. (2019). A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). Blood, 134, 1546.

Chicago

Sattva S. Neelapu, Roberto N. Miranda, Nathan Fowler, Auris Huen, Swami P. Iyer, Loretta J. Nastoupil, Sairah Ahmed, et al. 2019. “A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).” Blood 134 (November): 1546. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........3af209108dd0bd2f17aba784f6402bfd&authtype=sso&custid=ns315887.